Bone Cement Market: Market Size & Forecast 2026

The bone cement market encompasses polymethyl methacrylate (PMMA)-based products and related formulations that are used to fix prosthetic implants to bone during orthopedic surgeries. Total global revenue stood at roughly USD 3.82 billion in 2025, with a projected 7.4% CAGR pointing to a market in the USD 7-8 billion range by the mid-2030s depending on the forecast horizon. Demand is concentrated in arthroplasty applications, where bone cement remains the standard fixation method for cemented joint replacements.

• •Market valued at approximately USD 3.82 billion in 2025, growing at 7.4% CAGR.
• •Primary applications: hip and knee arthroplasty, vertebral augmentation, and trauma fixation.
• •Standard of care for cemented joint replacement remains PMMA-based formulations.

Demographic aging is the single largest growth driver, as the over-65 population expands fastest in North America, Europe, and parts of Asia, increasing the prevalence of degenerative joint disease and osteoporotic fractures. Rising surgical volumes for total hip and knee replacement, supported by improved access to elective orthopedic care in emerging markets, are accelerating unit demand. Adjacent trends such as hospital-acquired infection control, growing ambulatory surgery center adoption, and the use of antibiotic-loaded bone cement to reduce periprosthetic joint infection are also contributing to volume and value growth.

• •Aging populations in developed and emerging economies driving arthroplasty volumes.
• •Rising incidence of osteoarthritis, osteoporosis, and fragility fractures.
• •Adoption of antibiotic-loaded and premixed formulations to reduce surgical site infections.

The market segments by product type into traditional PMMA bone cement, antibiotic-loaded bone cement, premixed formulations, and bioactive or glass-based cements used in specialized spine and trauma applications. By end use, hospitals account for the majority of consumption, followed by ambulatory surgical centers and specialty orthopedic clinics. North America holds the leading revenue share due to high procedure volumes, while Europe is the second-largest market; the Asia-Pacific region is projected to record the highest growth rate over the forecast window on the back of expanding healthcare infrastructure and rising procedure uptake in China, India, and Japan.

• •Antibiotic-loaded cements are the fastest-growing product sub-segment.
• •Hospitals dominate end-user share, with ASCs growing fastest.
• •APAC projected to be the highest-growth regional segment through 2030.

What are the recent trends and outlook?

The medium-term outlook is supported by continued innovation in premixed antibiotic-loaded formulations, bioactive cements that promote bone integration, and syringe-based delivery systems that reduce operating-room prep time. Biodegradable and calcium-phosphate-based cements are gaining traction in spine and trauma applications, though PMMA remains the standard for arthroplasty. With an aging global population and steadily rising joint replacement volumes, the market is expected to sustain mid-to-high single-digit growth, with expansion in emerging markets providing additional upside.

• •Innovation focused on premixed antibiotic-loaded and syringe-delivered cements.
• •Bioactive and biodegradable alternatives gaining adoption in non-arthroplasty indications.
• •Long-term growth underpinned by global demographic aging and rising arthroplasty volumes.